How First-Time Biotechs Outpace Big Pharmas: McKinsey Report

Small but Mighty: How First-Time Biotech Launchers Are Outpacing Big Pharmas...First-time biotechs aren't just entering the scene, they're reshaping it. According to McKinsey & Company report, transformative shifts: 🧬An overwhelming 80% of tomorrow’s blockbusters reside in emerging biotech pipelines 🧬 Rare-disease focus delivers 1.7× greater launch success 🧬Portfolio diversification boosts long-term performance 🧬Commercial muscle and early capital are clear differentiators The bottom line for CEOs and Boards: Victory favours the strategic, not just the well‑funded. Your landmark launch can be the first of many ...but only if you invest wisely, diversify early, and execute relentlessly. 🔗 Read the full report here: https://lnkd.in/eHuGmpTr #biotech #asx #bioshares